Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPFZ.L Regulatory News (PFZ)

  • There is currently no data for PFZ

Form 38.5(b) - Pfizer Inc.

13 Nov 2015 11:40

RNS Number : 6795F
J.P. Morgan Securities LLC
13 November 2015
Β 

Ap27

Β 

FORMΒ 38.5(b)

Β 

IRISHΒ TAKEOVERΒ PANEL

Β 

DISCLOSUREΒ UNDERΒ RULEΒ 38.5(b)Β OFΒ THEΒ IRISHΒ TAKEOVERΒ PANEL ACT,Β 1997,Β TAKEOVERΒ RULES,Β 2013

Β 

DEALINGSΒ BYΒ CONNECTEDΒ EXEMPTΒ PRINCIPALΒ TRADERSΒ WITHOUTΒ RECOGNISEDΒ INTERMEDIARYΒ STATUS,Β ORΒ WITHΒ RECOGNISEDΒ INTERMEDIARYΒ STATUSΒ BUTΒ NOTΒ DEALINGΒ INΒ AΒ CLIENT-SERVINGΒ CAPACITY

Β 

Β 

1. KEYΒ INFORMATION

Β 

Name of exempt principal trader

J.P. Morgan Securities LLC.

Company dealt in

Pfizer Inc

Class of relevant security to which the dealings being disclosed relate (Note 1)

Common Stock

Date of dealing

12 November 2015

Β 

2. INTERESTSΒ ANDΒ SHORTΒ POSITIONS

Β 

(a) InterestsΒ andΒ shortΒ positionsΒ (followingΒ dealing)Β inΒ theΒ classΒ ofΒ relevantΒ securityΒ dealtΒ inΒ (NoteΒ 2)

Β 

Class of relevant security:

Long

Short

Common Stock

Number

(%)

Number

(%)

(1) Relevant securities

Β 5,061,776 0.08

2,679,291 0.04

(2) Derivatives (other than options)

1,309,645 0.02

Β 2,498,367 0.04

(3) Options and agreements to purchase/sell

Β 7,067,470 0.11

Β 3,895,600 0.06

Total

13,438,891 0.21

Β 9,073,258 0.14

Β 

Β 

Β 

(b) InterestsΒ andΒ shortΒ positionsΒ inΒ relevantΒ securitiesΒ ofΒ theΒ company,Β otherΒ thanΒ theΒ classΒ dealtΒ inΒ (NoteΒ 2)

Β 

Class of relevant security:

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

Β 

Ap28

Β 

Β 

3. DEALINGSΒ (NoteΒ 3)

Β 

(a) PurchasesΒ andΒ sales

Β 

Purchases/ sales

Β 

Number of relevant securities

Price per unit (USD)

Purchases

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Sales

15,800

2,400

13,400

2,896

3,900

100

5,042

72,142

7,900

17,505

113,073

2,900

200,370

3,013

4,300

1,750

849

18,400

1,986

300

864

3,500

43

200

Β 

493,623

249

1,398

100

1

180

33.3600

33.3650

33.3700

33.3729

33.3750

33.3775

33.3788

33.3800

33.3809

33.3831

33.3844

33.3898

33.3900

33.3940

33.3950

33.3951

33.3952

33.4000

33.4015

33.4050

33.4100

33.4200

33.5700

33.5750

Β 

33.3900

33.4905

33.5469

33.5500

33.5600

33.6028

Β 

(b) DerivativesΒ transactionsΒ (otherΒ thanΒ optionsΒ transactions)

Β 

Product name,

e.g. CFD

Nature of transaction

(Note 5)

Number of relevant securities

(Note 6)

Price per unit (USD)

(Note 4)

Equity Swap

Β 

Equity Link Note

Long

Β 

Long

Β 

Short

180,184

Β 

31,133

Β 

31,133

31,133

33.7400

Β 

32.1198

Β 

32.1198

32.1198

Β 

Β 

(c) OptionsΒ transactionsΒ inΒ respectΒ ofΒ existingΒ relevantΒ securities

Β 

Β 

(i) Writing,Β selling,Β purchasingΒ orΒ varying

Β 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 4)

Β 

Β 

(ii) Exercising

Β 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 4)

Β 

Β 

(d) OtherΒ dealingsΒ (includingΒ transactionsΒ inΒ respectΒ ofΒ newΒ securities)Β (NoteΒ 3)

Β 

Nature of transaction

(Note 7)

Details

Price per unit

(if applicable) (Note 4)

Β 

Ap29

Β 

4. OTHERΒ INFORMATION

Β 

Agreements,Β arrangementsΒ orΒ understandingsΒ relatingΒ toΒ optionsΒ orΒ derivatives

Β 

FullΒ detailsΒ ofΒ anyΒ agreement,Β arrangementΒ orΒ understandingΒ betweenΒ theΒ person disclosingΒ andΒ anyΒ otherΒ personΒ relatingΒ toΒ theΒ votingΒ rightsΒ ofΒ anyΒ relevantΒ securitiesΒ 

underΒ anyΒ optionΒ referredΒ toΒ onΒ thisΒ formΒ orΒ relatingΒ toΒ theΒ votingΒ rightsΒ orΒ future

Β acquisitionΒ orΒ disposalΒ ofΒ anyΒ relevantΒ securitiesΒ toΒ whichΒ anyΒ derivative referredΒ toΒ onΒ thisΒ formΒ isΒ referenced.Β IfΒ none,Β thisΒ shouldΒ beΒ stated.

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

IsΒ aΒ SupplementalΒ FormΒ 38.5(b)Β attached?Β (NoteΒ 8) Β YES

Β 

Β 

Date of disclosure

13 November 2015

Contact name

Tung Le

Telephone number

020 7742 7272

Name of offeree/offeror with which connected

Allergan plc

Nature of connection (Note 9)

Adviser to Allergan plc

Β 

Β 

Β 

SUPPLEMENTALΒ FORMΒ 38.5(b)

Β 

Β 

Β 

Β 

IRISHΒ TAKEOVERΒ PANEL

Β 

DISCLOSUREΒ UNDERΒ RULEΒ 38.5(b)Β OFΒ THEΒ IRISHΒ TAKEOVERΒ PANEL ACT,Β 1997,Β TAKEOVERΒ RULES,Β 2013

Β 

DETAILSΒ OFΒ OPENΒ POSITIONS

Β 

(ThisΒ formΒ shouldΒ beΒ attachedΒ toΒ FormΒ 38.5(b))Β OPENΒ POSITIONSΒ (NoteΒ 1)

Β 

Product name,

e.g. call option

Written or purchased

Number of relevant securities to which the option or derivative relates

Exercise price (Note 2)(USD)

Type, e.g. American, European etc.

Expiry date

Call option

Purchased

30,000

35.00

American

20/01/17

Call option

Purchased

70,000

37.00

American

20/01/17

Call option

Purchased

363,900

35.00

American

15/01/16

Call option

Purchased

700

38.00

American

15/01/16

Call option

Purchased

1,200,000

34.00

American

20/11/15

Call option

Purchased

1,500,000

35.00

American

13/11/15

Call option

Written

Β 

2,500

28.00

American

15/01/16

Call option

Written

14,700

30.00

American

15/01/16

Call option

Written

200

37.00

American

15/01/16

Call option

Written

150,000

37.00

American

15/01/16

Call option

Written

50,000

33.00

American

18/12/15

Call option

Written

47,100

34.00

American

18/12/15

Call option

Written

7,600

32.00

American

15/01/16

Call option

Purchased

383,200

34.71

European

21/05/16

Call option

Purchased

383,200

34.71

European

21/05/16

Call option

Purchased

127,794

35.28

European

03/12/15

Call option

Purchased

120,533

35.66

European

12/01/16

Call option

Purchased

48,943

36.47

European

25/01/16

Call option

Purchased

200,000

33.00

European

16/12/15

Call option

Written

200,000

33.00

European

16/12/16

Call option

Written

383,200

34.71

European

21/12/15

Put option

Written

Β 

30,000

35.00

American

20/01/17

Put option

Written

Β 

20,000

35.00

American

20/01/17

Put option

Written

Β 

4,300

30.00

American

15/01/16

Put option

Written

Β 

2,800

28.00

American

15/01/16

Put option

Written

Β 

300

32.00

American

15/01/16

Put option

Written

Β 

150,000

30.00

American

16/09/16

Put option

Written

Β 

100,000

36.00

American

18/03/16

Put option

Written

Β 

32,900

32.00

American

15/01/16

Put Option

Written

1,500,000

35.00

American

17/06/16

Put option

Purchased

9,200

33.00

American

19/02/16

Put option

Purchased

19,100

31.00

American

19/02/16

Put option

Purchased

5,300

23.00

American

15/01/16

Put option

Purchased

100,000

30.00

American

15/01/16

Put option

Purchased

5,600

25.00

American

15/01/16

Put option

Purchased

250,000

28.00

American

15/01/16

Put option

Written

200,000

33.00

European

16/12/16

Put Option

Purchased

1,500,000

34.50

American

13/11/15

Put option

Purchased

450,000

35.00

American

15/01/16

Callable Barrier Reverse Convertible Note

Purchased

183,430

32.71

N/A

21/03/17

Callable Barrier Reverse Convertible Note

Purchased

30,572

32.71

N/A

21/03/17

Auto-callable Barrier Reverse Convertible Note

Purchased

45,984

32.62

N/A

17/03/17

Barrier Reverse Convertible Note

Purchased

30,408

34.53

N/A

05/04/16

Equity Linked Note

Purchased

6,740

29.67

N/A

03/02/16

Leveraged Accumulator

Purchased

15,614+

29.12

N/A

12/09/16

Callable Barrier Reverse Convertible Note

Written

183,430

32.71

N/A

21/03/17

Callable Barrier Reverse Convertible Note

Written

30,572

32.71

N/A

21/03/17

Auto-Callable Barrier Reverse Convertible Note

Written

45,984

32.62

N/A

17/03/17

Barrier Reverse Convertible Note

Written

30,408

34.53

N/A

05/04/16

Equity Linked Note

Written

6,740

29.67

N/A

03/02/16

Leveraged Accumulator

Written

15,614+

29.12

N/A

12/09/16

Leveraged Accumulator

Written

9,000+

31.70

N/A

04/03/16

Auto-callable Optimization Securities

Written

7,851

27.60

N/A

25/06/20

Equity Linked Note

Written

6,740

29.67

N/A

03/02/16

Callable Barrier Reverse Convertible Note

Written

183,430

32.71

N/A

21/03/17

Callable Barrier Reverse Convertible Note

Written

30,572

32.71

N/A

21/03/17

Auto-Callable Barrier Reverse Convertible Note

Written

45,984

32.62

N/A

17/03/17

Barrier Reverse Convertible Note

Written

30,408

34.53

N/A

05/04/16

Leveraged Accumulator

Written

15,614+

29.12

N/A

12/09/16

Put Option

Purchased

457,000

27.50

N/A

11/01/16

Callable Barrier Reverse Convertible

Purchased

22,929

32.71

N/A

21/03/17

Auto-Callable Barrier Reverse Convertible Note

Purchased

7,685

32.53

N/A

15/03/17

Auto-Callable Barrier Reverse Convertible Note

Purchased

11,189

32.62

N/A

17/03/17

Barrier Reverse Convertible Note

Purchased

178

2.44

N/A

05/04/16

Put Option

Written

500,000

33.00

American

18/03/16

Put Option

Purchased

1,000,000

33.50

American

20/11/15

+ This instrument is physically settled, and the interest in shares has been calculated as the maximum number of Mylan shares that the counterparty could be obliged to buy at the exercise price

Β 

Notes

Β 

1. WhereΒ thereΒ areΒ openΒ optionΒ positionsΒ orΒ openΒ derivativeΒ positionsΒ exceptΒ forΒ CFDs),Β fullΒ detailsΒ shouldΒ beΒ given.Β FullΒ detailsΒ ofΒ any existingΒ agreementsΒ toΒ purchaseΒ orΒ toΒ sellΒ mustΒ alsoΒ beΒ givenΒ onΒ this form.

Β 

2. ForΒ allΒ pricesΒ andΒ otherΒ monetaryΒ amounts,Β theΒ currencyΒ mustΒ be stated.

Β 

ForΒ fullΒ detailsΒ ofΒ disclosureΒ requirements,Β seeΒ RulesΒ 8Β and

38.5Β ofΒ theΒ Rules.Β IfΒ inΒ doubt,Β consultΒ theΒ Panel.

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
ISEFFWFFDFISEDF
Date   Source Headline
7th May 201411:20 amBUSForm 8.3 - Pfizer Inc
7th May 201410:40 amRNSForm 8.5 (EPT/RI) astrazeneca PLC
7th May 201410:38 amRNSForm 8.5 (EPT/RI) Astrazeneca PLC
7th May 201410:36 amRNSForm 8.5 (EPT/RI) Pfizer INC
7th May 201410:31 amRNSRule 2.10 Announcement
7th May 201410:30 amRNSForm 8.5 (EPT/RI) Astrazeneca PLC
7th May 201410:29 amRNSForm 8.5 (EPT/RI) Pfizer Inc
7th May 20147:00 amRNSBENEFITS OF A COMBINATION WITH ASTRAZENECA
7th May 20147:00 amRNSForm 8.5 (EPT/NON-RI)
6th May 20146:16 pmRNSForm 8 (DD) - [Pfizer Inc] - Amendment
6th May 20146:08 pmRNSForm 8.5 (EPT/NON-RI)(OPD)
6th May 20145:15 pmRNSForm 8 (DD) - Pfizer Inc.
6th May 20144:46 pmRNSForm 8.3 - Pfizer Inc
6th May 20144:42 pmRNSForm 8.3 - Pfizer Inc
6th May 20144:16 pmRNSForm 8.5 (EPT/RI)replacement - Pfizer Inc
6th May 20144:14 pmRNSForm 8.5 (EPT/RI) Replacement - Pfizer Inc
6th May 20144:11 pmRNSForm 8.5 (EPT/RI)Replacement - Pfizer Inc
6th May 20144:07 pmRNSForm 8.5 (EPT/RI)Replacement - Pfizer Inc
6th May 20144:05 pmRNSForm 8.5 (EPT/RI) Replacement - Pfizer Inc
6th May 20144:04 pmRNSForm 8.5 (EPT/RI)replacement - Pfizer Inc
6th May 20144:02 pmBUSForm 8.3 - PFIZER INC
6th May 20143:56 pmRNSForm 8.5 (EPT/RI)Replacement - Astrazeneca PLC
6th May 20143:53 pmRNSForm 8.5 (EPT/RI) Replacement - Astrazeneca PLC
6th May 20143:51 pmRNSForm 8.5 (EPT/RI)Replacement - Astrazeneca PLC
6th May 20143:51 pmRNSForm 8.5 (EPT/RI)Replacement - Astrazeneca PLC
6th May 20143:49 pmRNSForm 8.5 (EPT/RI) Replacement - Astrazeneca PLC
6th May 20143:46 pmRNSForm 8.5 (EPT/RI)replacement - Astrazeneca PLC
6th May 20143:34 pmRNSForm 8.3 - Pfizer Inc
6th May 20143:23 pmRNSForm 8.3 - Pfizer Inc
6th May 20143:19 pmRNSForm 8.3 - Pfizer Inc
6th May 20143:19 pmRNSForm 8.3 - Pfizer Inc
6th May 20143:18 pmRNSForm 8.3 - astrazeneca plc
6th May 20143:16 pmRNSForm 8.3 - PFIZER INC
6th May 20143:15 pmRNSForm 8.3 - AstraZeneca Plc
6th May 20143:14 pmBUSForm 8.3 - Pfizer Inc.
6th May 20143:00 pmRNSForm 8.3 - Pfizer Inc.
6th May 20142:51 pmRNSForm 8.3 - [PFIZER INC]
6th May 20142:48 pmBUSForm 8.3 - Pfizer Inc
6th May 20142:31 pmRNSForm 8.3 - [Pfizer/Astrazeneca]
6th May 20141:54 pmRNSForm 8.3 - Pfizer Inc
6th May 20141:48 pmRNSForm 8.3 - AstraZeneca Plc
6th May 20141:28 pmRNSForm 8.3 - Pfizer Inc
6th May 20141:25 pmRNSForm 8.3 - AstraZeneca Plc
6th May 20141:20 pmRNSForm 8.3 - [AstraZeneca Plc]
6th May 20141:14 pmBUSForm 8.3 - Pfizer Inc.
6th May 20141:13 pmRNSForm 8.5 (EPT/RI)
6th May 20141:09 pmRNSForm 8.5 (EPT/NON-RI)
6th May 20141:07 pmBUSForm 8.3 - Pfizer Inc.
6th May 20141:06 pmRNSForm 8.5 (EPT/RI)
6th May 201412:35 pmRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.